secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bioventus Inc. (BVS)
CIK:        0001665988
Form:       8-K
Filed at:   2025-11-04T23:59:59+00:00
Accession:  0001665988-25-000025
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bioventus Q3 GAAP EPS $0.05 vs -$0.08 YoY; organic revenue +8% to $138.7M
-------------------------------------------------------------------------

- GAAP net income $3.2M vs $5.2M loss; diluted EPS $0.05 improved from -$0.08 YoY.
- Non-GAAP EPS $0.15, up 200% from $0.05; Adjusted EBITDA $26.6M (+12.9%) with margin 19.2%.
- Organic revenue growth 8.2% led by Pain Treatments (+6.4%) and Surgical Solutions (+9.3%).
- Cash from operations $30.1M, +192% YoY; reaffirms FY2025 revenue $560-570M and Adj. EBITDA $112-116M.
- Entered new credit agreement with $300M term loan and $100M revolver, reducing annual interest by ~$2M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1665988/000166598825000025/0001665988-25-000025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1665988/000166598825000025/bvs-20251104.htm
  HTML page:      https://secwatch.observer/filing/0001665988-25-000025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer